Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 4309.44
MASI's Cash to Debt is ranked higher than
71% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. MASI: 4309.44 )
Ranked among companies with meaningful Cash to Debt only.
MASI' s Cash to Debt Range Over the Past 10 Years
Min: 0.49  Med: 513.4 Max: No Debt
Current: 4309.44
Equity to Asset 0.68
MASI's Equity to Asset is ranked higher than
59% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. MASI: 0.68 )
Ranked among companies with meaningful Equity to Asset only.
MASI' s Equity to Asset Range Over the Past 10 Years
Min: -3.07  Med: 0.66 Max: 0.81
Current: 0.68
-3.07
0.81
Interest Coverage N/A
MASI's Interest Coverage is ranked higher than
71% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 97.42 vs. MASI: N/A )
Ranked among companies with meaningful Interest Coverage only.
MASI' s Interest Coverage Range Over the Past 10 Years
Min: 27.05  Med: N/A Max: No Debt
Current: N/A
F-Score: 9
Z-Score: 12.51
M-Score: -2.85
WACC vs ROIC
8.17%
91.62%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 60.58
MASI's Operating margin (%) is ranked higher than
99% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. MASI: 60.58 )
Ranked among companies with meaningful Operating margin (%) only.
MASI' s Operating margin (%) Range Over the Past 10 Years
Min: 14.57  Med: 21.48 Max: 60.58
Current: 60.58
14.57
60.58
Net-margin (%) 43.28
MASI's Net-margin (%) is ranked higher than
99% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. MASI: 43.28 )
Ranked among companies with meaningful Net-margin (%) only.
MASI' s Net-margin (%) Range Over the Past 10 Years
Min: 10.4  Med: 13.87 Max: 43.28
Current: 43.28
10.4
43.28
ROE (%) 86.80
MASI's ROE (%) is ranked higher than
100% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. MASI: 86.80 )
Ranked among companies with meaningful ROE (%) only.
MASI' s ROE (%) Range Over the Past 10 Years
Min: 17.28  Med: 22.79 Max: 86.8
Current: 86.8
17.28
86.8
ROA (%) 45.75
MASI's ROA (%) is ranked higher than
99% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 0.07 vs. MASI: 45.75 )
Ranked among companies with meaningful ROA (%) only.
MASI' s ROA (%) Range Over the Past 10 Years
Min: 12.07  Med: 16.6 Max: 45.75
Current: 45.75
12.07
45.75
ROC (Joel Greenblatt) (%) 240.73
MASI's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. MASI: 240.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MASI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 78.21  Med: 141.81 Max: 277.99
Current: 240.73
78.21
277.99
Revenue Growth (3Y)(%) 11.10
MASI's Revenue Growth (3Y)(%) is ranked higher than
75% of the 224 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. MASI: 11.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MASI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -19.3  Med: 12.35 Max: 30.3
Current: 11.1
-19.3
30.3
EBITDA Growth (3Y)(%) 73.10
MASI's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. MASI: 73.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MASI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 10.7 Max: 287.2
Current: 73.1
0
287.2
EPS Growth (3Y)(%) 76.90
MASI's EPS Growth (3Y)(%) is ranked higher than
90% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. MASI: 76.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MASI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -33.8  Med: 8.1 Max: 76.9
Current: 76.9
-33.8
76.9
GuruFocus has detected 4 Warning Signs with Masimo Corp $MASI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MASI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

MASI Guru Trades in Q1 2016

Joel Greenblatt 13,804 sh (New)
John Hussman 325,000 sh (+160.00%)
Jim Simons 232,700 sh (+4.63%)
Paul Tudor Jones 12,662 sh (+2.94%)
Mario Gabelli 131,400 sh (-0.45%)
Jeremy Grantham 30,800 sh (-0.96%)
Chuck Royce 115,000 sh (-36.81%)
» More
Q2 2016

MASI Guru Trades in Q2 2016

Steven Cohen 73,300 sh (New)
Paul Tudor Jones 13,464 sh (+6.33%)
Joel Greenblatt 14,017 sh (+1.54%)
Chuck Royce 115,000 sh (unchged)
Jeremy Grantham Sold Out
Mario Gabelli 130,200 sh (-0.91%)
John Hussman 268,000 sh (-17.54%)
Jim Simons 143,800 sh (-38.20%)
» More
Q3 2016

MASI Guru Trades in Q3 2016

Joel Greenblatt 27,968 sh (+99.53%)
Steven Cohen 83,700 sh (+14.19%)
Mario Gabelli 130,200 sh (unchged)
Chuck Royce 115,000 sh (unchged)
Paul Tudor Jones 12,982 sh (-3.58%)
John Hussman 200,000 sh (-25.37%)
Jim Simons 78,500 sh (-45.41%)
» More
Q4 2016

MASI Guru Trades in Q4 2016

Columbia Wanger 838,230 sh (New)
Steven Cohen 195,100 sh (+133.09%)
Jim Simons 173,400 sh (+120.89%)
Joel Greenblatt 39,433 sh (+40.99%)
Mario Gabelli 130,000 sh (-0.15%)
John Hussman 102,000 sh (-49.00%)
Chuck Royce 57,300 sh (-50.17%)
Paul Tudor Jones 4,862 sh (-62.55%)
» More
» Details

Insider Trades

Latest Guru Trades with MASI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NAS:NUVA, OTCPK:FSPKF, NAS:ABMD, OTCPK:EKTAY, NAS:IART, OTCPK:GGNDF, OTCPK:CNVVY, OTCPK:CHEOY, NAS:WMGI, NYSE:NVRO, OTCPK:SDMHF, NYSE:GMED, NYSE:PEN, NAS:LIVN, NAS:ZLTQ, OTCPK:NHNKY, NAS:CYNO, NAS:INGN, OTCPK:IOBCF, NAS:BABY » details
Traded in other countries:3M4.Germany,
Masimo Corp is a medical technology company. The Company develops, manufactures, and markets noninvasive monitoring technologies. Its product includes noninvasive blood constituent and brain and breath monitoring.

Masimo Corp was incorporated in California in May 1989 and reincorporated in Delaware in May 1996. The Company is a medical technology company that develops, manufactures, and markets a variety of noninvasive monitoring technologies. It provides products directly and through distributors and original equipment manufacturers (OEM) partners to hospitals, emergency medical service (EMS) providers, physician offices, veterinarians, long term care facilities and consumers. Its business is Measure-through-Motion and Low-Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its products offering include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, and electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. In addition, it has also developed Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor and the Radius-7 wearable wireless patient monitor. It also developed the Patient SafetyNet remote patient surveillance monitoring system, which allows up to 200 patients to be monitored simultaneously and remotely through a PC-based viewing station or by care providers through their pagers, voice-over-IP phones or smartphones. The Company's solutions and related products are based upon its proprietary Masimo SET and rainbow algorithms. It also provides technologies to OEMs in a form factor that is easy to integrate into their patient monitors, defibrillators and infant incubators. It also develops, manufactures and markets patient monitoring technologies that incorporate a monitor or circuit board and sensors, including proprietary single-patient-use, reusable and rainbow ReSposable sensors and patient cables. In addition, it offers remote alarm/monitoring solutions, software and connectivity solutions. Its product components includes Patient Monitoring Solutions including Circuit Boards and Modules, a signal processing apparatus for all Masimo technology platforms, Monitors and Devices, Patient Monitoring and Connectivity Platforms, Sensors, Line Filters and Mainstream Adapters, Remote Alarm and Monitoring Solutions, Proprietary Measurement, and Connectivity; and Consumer Monitoring Solutions including Devices. The Company is subject to U.S. Food, Drug, and Cosmetic Act (FDCA) and the regulations promulgated under that Act, the FDA regulates the design, development, clinical trials, testing, manufacture, packaging, labeling, storage, distribution and promotion of medical devices.

Top Ranked Articles about Masimo Corp

Weekly CEO Sells Highlight: Gentex Corp, Masimo Corp, The Michaels Companies, Boyd Gaming Corp
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Gentex Corp., Masimo Corp., The Michaels Companies Inc., Boyd Gaming Corp. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 15.35
MASI's P/E(ttm) is ranked higher than
79% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.50 vs. MASI: 15.35 )
Ranked among companies with meaningful P/E(ttm) only.
MASI' s P/E(ttm) Range Over the Past 10 Years
Min: 10.85  Med: 25.49 Max: 69.65
Current: 15.35
10.85
69.65
Forward P/E 37.59
MASI's Forward P/E is ranked lower than
77% of the 56 Companies
in the Global Medical Devices industry.

( Industry Median: 23.92 vs. MASI: 37.59 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 15.35
MASI's PE(NRI) is ranked higher than
79% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 25.48 vs. MASI: 15.35 )
Ranked among companies with meaningful PE(NRI) only.
MASI' s PE(NRI) Range Over the Past 10 Years
Min: 10.85  Med: 25.49 Max: 69.65
Current: 15.35
10.85
69.65
Price/Owner Earnings (ttm) 12.65
MASI's Price/Owner Earnings (ttm) is ranked higher than
84% of the 103 Companies
in the Global Medical Devices industry.

( Industry Median: 30.29 vs. MASI: 12.65 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MASI' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.97  Med: 31.14 Max: 160.32
Current: 12.65
8.97
160.32
P/B 7.75
MASI's P/B is ranked lower than
81% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 3.17 vs. MASI: 7.75 )
Ranked among companies with meaningful P/B only.
MASI' s P/B Range Over the Past 10 Years
Min: 3.53  Med: 6.04 Max: 15.19
Current: 7.75
3.53
15.19
P/S 6.59
MASI's P/S is ranked lower than
75% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 3.29 vs. MASI: 6.59 )
Ranked among companies with meaningful P/S only.
MASI' s P/S Range Over the Past 10 Years
Min: 1.77  Med: 3.41 Max: 8.26
Current: 6.59
1.77
8.26
PFCF 11.73
MASI's PFCF is ranked higher than
84% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. MASI: 11.73 )
Ranked among companies with meaningful PFCF only.
MASI' s PFCF Range Over the Past 10 Years
Min: 8.3  Med: 29.21 Max: 2401.82
Current: 11.73
8.3
2401.82
POCF 11.02
MASI's POCF is ranked higher than
78% of the 135 Companies
in the Global Medical Devices industry.

( Industry Median: 18.12 vs. MASI: 11.02 )
Ranked among companies with meaningful POCF only.
MASI' s POCF Range Over the Past 10 Years
Min: 7.81  Med: 21.41 Max: 51.39
Current: 11.02
7.81
51.39
EV-to-EBIT 8.31
MASI's EV-to-EBIT is ranked higher than
89% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 21.48 vs. MASI: 8.31 )
Ranked among companies with meaningful EV-to-EBIT only.
MASI' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.1  Med: 16.5 Max: 34.5
Current: 8.31
6.1
34.5
EV-to-EBITDA 8.04
MASI's EV-to-EBITDA is ranked higher than
84% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 15.79 vs. MASI: 8.04 )
Ranked among companies with meaningful EV-to-EBITDA only.
MASI' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.7  Med: 14.95 Max: 32.1
Current: 8.04
5.7
32.1
PEG 0.45
MASI's PEG is ranked higher than
91% of the 76 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. MASI: 0.45 )
Ranked among companies with meaningful PEG only.
MASI' s PEG Range Over the Past 10 Years
Min: 0.45  Med: 9.64 Max: 617.25
Current: 0.45
0.45
617.25
Shiller P/E 55.94
MASI's Shiller P/E is ranked lower than
55% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 49.62 vs. MASI: 55.94 )
Ranked among companies with meaningful Shiller P/E only.
MASI' s Shiller P/E Range Over the Past 10 Years
Min: 20.24  Med: 31.54 Max: 56.29
Current: 55.94
20.24
56.29
Current Ratio 2.30
MASI's Current Ratio is ranked lower than
53% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. MASI: 2.30 )
Ranked among companies with meaningful Current Ratio only.
MASI' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 2.54 Max: 4.87
Current: 2.3
1.35
4.87
Quick Ratio 1.97
MASI's Quick Ratio is ranked higher than
53% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. MASI: 1.97 )
Ranked among companies with meaningful Quick Ratio only.
MASI' s Quick Ratio Range Over the Past 10 Years
Min: 1.15  Med: 2.02 Max: 4.34
Current: 1.97
1.15
4.34
Days Inventory 103.24
MASI's Days Inventory is ranked higher than
63% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 130.88 vs. MASI: 103.24 )
Ranked among companies with meaningful Days Inventory only.
MASI' s Days Inventory Range Over the Past 10 Years
Min: 99.78  Med: 106.83 Max: 117.9
Current: 103.24
99.78
117.9
Days Sales Outstanding 53.45
MASI's Days Sales Outstanding is ranked higher than
70% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 66.78 vs. MASI: 53.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
MASI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.51  Med: 45.82 Max: 53.45
Current: 53.45
36.51
53.45
Days Payable 49.22
MASI's Days Payable is ranked lower than
55% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 58.05 vs. MASI: 49.22 )
Ranked among companies with meaningful Days Payable only.
MASI' s Days Payable Range Over the Past 10 Years
Min: 42.89  Med: 62.88 Max: 72.6
Current: 49.22
42.89
72.6

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.90
MASI's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. MASI: 3.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MASI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -79.8  Med: -1.65 Max: 4.3
Current: 3.9
-79.8
4.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 95.16
MASI's Price/Net Cash is ranked lower than
92% of the 114 Companies
in the Global Medical Devices industry.

( Industry Median: 17.13 vs. MASI: 95.16 )
Ranked among companies with meaningful Price/Net Cash only.
MASI' s Price/Net Cash Range Over the Past 10 Years
Min: 14.49  Med: 50.39 Max: 290.7
Current: 95.16
14.49
290.7
Price/Net Current Asset Value 17.60
MASI's Price/Net Current Asset Value is ranked lower than
79% of the 234 Companies
in the Global Medical Devices industry.

( Industry Median: 6.59 vs. MASI: 17.60 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MASI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 6.27  Med: 10.73 Max: 36.08
Current: 17.6
6.27
36.08
Price/Tangible Book 8.51
MASI's Price/Tangible Book is ranked lower than
74% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 4.24 vs. MASI: 8.51 )
Ranked among companies with meaningful Price/Tangible Book only.
MASI' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.11  Med: 6.46 Max: 14.94
Current: 8.51
4.11
14.94
Price/Projected FCF 2.25
MASI's Price/Projected FCF is ranked lower than
54% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 2.11 vs. MASI: 2.25 )
Ranked among companies with meaningful Price/Projected FCF only.
MASI' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.71  Med: 1.75 Max: 3.75
Current: 2.25
1.71
3.75
Price/Median PS Value 1.93
MASI's Price/Median PS Value is ranked lower than
87% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 0.99 vs. MASI: 1.93 )
Ranked among companies with meaningful Price/Median PS Value only.
MASI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.73  Med: 1.05 Max: 1.94
Current: 1.93
0.73
1.94
Price/Peter Lynch Fair Value 0.68
MASI's Price/Peter Lynch Fair Value is ranked higher than
91% of the 53 Companies
in the Global Medical Devices industry.

( Industry Median: 1.74 vs. MASI: 0.68 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MASI' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.53  Med: 0.96 Max: 3.47
Current: 0.68
0.53
3.47
Price/Graham Number 2.41
MASI's Price/Graham Number is ranked lower than
55% of the 139 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. MASI: 2.41 )
Ranked among companies with meaningful Price/Graham Number only.
MASI' s Price/Graham Number Range Over the Past 10 Years
Min: 1.8  Med: 2.84 Max: 6.61
Current: 2.41
1.8
6.61
Earnings Yield (Greenblatt) (%) 11.98
MASI's Earnings Yield (Greenblatt) (%) is ranked higher than
95% of the 337 Companies
in the Global Medical Devices industry.

( Industry Median: -0.30 vs. MASI: 11.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MASI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.9  Med: 6 Max: 16.4
Current: 11.98
2.9
16.4
Forward Rate of Return (Yacktman) (%) 25.18
MASI's Forward Rate of Return (Yacktman) (%) is ranked higher than
87% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 8.88 vs. MASI: 25.18 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MASI' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -31.9  Med: 3.7 Max: 26.1
Current: 25.18
-31.9
26.1

More Statistics

Revenue (TTM) (Mil) $694.6
EPS (TTM) $ 5.65
Beta0.79
Short Percentage of Float4.85%
52-Week Range $33.03 - 85.94
Shares Outstanding (Mil)50.42

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 752 812 887
EPS ($) 2.27 2.56 2.75
EPS w/o NRI ($) 2.27 2.56 2.75
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for MASI

Headlines

Articles On GuruFocus.com
John Hussman's Top-Performing Stocks Jul 05 2016 
Weekly CEO Sells Highlight: Gentex Corp, Masimo Corp, The Michaels Companies Inc, Boyd Gaming Corp. Jun 13 2016 
BTIM Corp's Top Buys in Q2 2015 Jul 20 2015 
Meridian Funds' Top Five Second Quarter Increases Jul 30 2013 
Weekly CEO Buys Highlight: MDR, MASI, FCH, FGP, FUR Jun 10 2012 
Masimo Corp. CEO Joe Kiani Buys 50,000 Shares Jun 04 2012 
Weekly CEO Buys Highlight: KMI, VGR, SIRO, PNK, MASI Nov 27 2011 
Weekly CEO Buys Highlight: SLM, MASI, ITRI, FLS, PG Nov 05 2011 
Weekly CEO Buys Highlight: MASI, ITRI, FSL, PTP, SLB Oct 29 2011 
Masimo Corp. Reports Operating Results (10-K) Feb 16 2011 

More From Other Websites
Can Penumbra (PEN) Spring a Surprise this Earnings Season? Feb 22 2017
Patterson Companies (PDCO) Q3 Earnings: What's in Store? Feb 21 2017
Masimo Announces Recent Study Monitoring Methemoglobin Levels During Administration of Inhaled... Feb 21 2017
Medtronic (MDT) Q3 Earnings: Disappointment in the Cards? Feb 20 2017
MASIMO CORP Financials Feb 18 2017
Masimo Corp. :MASI-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017 Feb 16 2017
Masimo Gets CE Mark for RRp on MightySat Rx Pulse Oximeter Feb 16 2017
Masimo Corp. :MASI-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017 Feb 15 2017
Masimo Announces CE Marking of Respiration Rate Measurement on MightySat™ Rx Feb 15 2017
Masimo Announces CE Marking of Respiration Rate Measurement on MightySat™ Rx Feb 15 2017
Edited Transcript of MASI earnings conference call or presentation 14-Feb-17 9:30pm GMT Feb 14 2017
Masimo misses 4Q profit forecasts Feb 14 2017
Masimo misses 4Q profit forecasts Feb 14 2017
MASIMO CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 14 2017
Masimo Corp Earnings Call scheduled for 4:30 pm ET today Feb 14 2017
Masimo Reports Fourth Quarter and Fiscal Year 2016 Financial Results Feb 14 2017
Q4 2016 Masimo Corp Earnings Release - After Market Close Feb 14 2017
Masimo downgraded by Raymond James Feb 13 2017
Post Earnings Coverage as Align Technology's Revenue Soared 27.3%; Record $1 Billion Annual Revenue Feb 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)